同时摄入罗斯瓦斯塔丁和氧化的临床影响:多中心,随机,并行组试验
Akio Nakashima1,2, Kaoko Tokura1, Momoko Misaki1
1Department of Pharmacy, Fukuoka University Chikushi Hospital, 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka 818-8502, Japan.
Journal of clinical medicine research
|November 10, 2025
概括
同时使用罗斯瓦斯塔丁 (RSV) 和氧化 (MgO) 并没有显著影响降低LDL-C. 简化药物管理可以改善服用多种药物的患者的药物坚持.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 心血管研究研究心血管研究
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 罗斯瓦斯塔丁 (RSV) 有效降低了LDL-C,但其吸收被氧化 (MgO) 降低.
- 这种相互作用引起了人们对RSV在与MgO联合使用时的临床疗效的担忧.
研究的目的:
- 为了评估RSV和MGO同时服用与分阶段服用对LDL-C水平的影响.
- 评估施用时间对罗斯瓦斯塔丁治疗疗效的影响.
主要方法:
- 一个多中心,随机,并行组试验,比较同时或分阶段 (≥2h) 的MGO和RSV给药.
- 在基线和12周收集了人口统计和脂质资料 (LDL-C,总胆固醇,HDL-C,甘油三) 的数据.
- 监测药物坚持,包括在最终分析中≥80%遵守药物的患者.
主要成果:
- 45名患者完成了该研究 (25名控制组,20名干预组) 具有类似的基线特征.
- 在12周后,同步和分阶段服用组之间的LDL-C降低率没有显著差异 (P = 0.9091).
结论:
- 同时使用罗斯瓦斯塔丁和氧化并没有显著改变LDL-C的降低,相比分阶段的管理.
- 简化药物治疗计划可以提高药物服药,特别是对于老年患者或多药患者.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189
Bioavailability Study Design: Healthy Subjects Versus Patients
137
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
137
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188
Time Course of Drug Effect
2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K

